$ Value
$3.4M
Shares
21,721
Price
$158
Filed
Oct 20
Insider
Name
REED JOHN C
Title
EVP, Innovative Medicine, R&D
CIK
0001181561
Roles
Transaction Details
Transaction Date
2025-10-17
Code
M
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
43,442
Footnotes
This transaction was executed in multiple trades at prices ranging from $192.69 to $192.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date.
Filing Info
REED JOHN C's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2025-10-17 | JNJ | M | $3.4M |
| 2025-10-17 | JNJ | ▼ | $4.2M |
| 2025-10-17 | JNJ | M | $3.4M |
| 2025-07-17 | JNJ | ▼ | $3.1M |
| 2025-05-01 | JNJ | M | $0 |
| 2025-05-01 | JNJ | F | $1.7M |
| 2025-05-01 | JNJ | M | $0 |
Other Insiders at JNJ (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Duato Joaquin
CEO and Chairman of the Board
|
— | $22.1M | 2026-01-26 |
|
Wengel Kathryn E
EVP, Chief TO and Risk Officer
|
— | — | 2026-02-06 |
|
Forminard Elizabeth
EVP, Chief Legal Officer
|
— | — | 2026-02-05 |
|
Mulholland Kristen
EVP, Chief HR Officer
|
— | — | 2026-02-06 |